Robbert J. van Alphen

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld et al. · The Lancet Oncology · 2023 · 168 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Janet R. Vos, Ingrid E. Fakkert, Joanne A. de Hullu et al. · JNCI Journal of the National Cancer Institute · 2019 · 69 citations · Full text

Medicine, Genetics, Oncology +17

Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin

Maja J.A. de Jonge, Jaap Verweij, Peter de Bruijn et al. · Journal of Clinical Oncology · 2000 · 61 citations

Medicine, Oncology, Pharmacology +15

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

Anne‐Joy M. de Graan, Sebastiaan F. Teunissen, Filip De Vos et al. · Journal of Clinical Oncology · 2011 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen

Koen G. A. M. Hussaarts, Daan P. Hurkmans, Esther Oomen‐de Hoop et al. · Cancers · 2019 · 50 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16